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Abstract
Methotrexate has been used an immunomodulator in 
many autoimmune diseases, including inflammatory 
bowel disease. However, many physicians are unfamiliar 
or uncomfortable with its use in the management of 
inflammatory bowel disease. We summarize the data 
for use of methotrexate in common clinical scenarios: 
(1) steroid dependant Crohn’s disease (CD); (2) mainte-
nance of remission in steroid free CD; (3) azathioprine 
failures in CD; (4) in combination therapy with Anti-
TNF agents in CD; (5) decreasing antibody formation to 
Anti-TNF therapy in CD; (6) management of fistulizing 
disease in CD; and (7) as well as induction and mainte-
nance of remission in ulcerative colitis. An easy to use 
algorithm is provided for the busy clinician to access 
and safely prescribe methotrexate for their inflamma-
tory bowel disease patients. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Methotrexate can a be a useful adjunct to the 
treatment of inflammatory bowel disease, but many 
practitioners are unfamiliar with it’s use. Here, we have 
provided a succinct summary of the data behind the 
use of methotrexate and a short “user’s guide” and 
algorithm to allow for the busy clinician to become 
quickly familiar with the drug and information to help 
prescribe it safely. 
Swaminath A, Taunk R, Lawlor G. Use of methotrexate in in-
flammatory bowel disease in 2014: A User’s Guide. World J Gas-
trointest Pharmacol Ther 2014; 5(3): 113-121  Available from: 
URL: http://www.wjgnet.com/2150-5349/full/v5/i3.113.htm 
DOI: http://dx.doi.org/10.4292/wjgpt.v5.i3.113
INTRODUCTION
Methotrexate (MTX) has a long history for effectively 
treating rheumatological conditions such as rheumatoid 
arthritis (RA), systemic lupus erythematosus (SLE) and 
sarcoidosis[1-3]. Over the past 25 years there have been nu-
merous studies that evaluated its efficacy in Inflammatory 
Bowel Disease with varied results. It has to date remained 
in treatment algorithms as a salvage therapy for patients 
who have failed, or become intolerant of, azathioprine. 
The goal of  our paper is to summarize the data behind 
methotrexate for common clinical situations and to pro-
vide a quick access guide on prescribing the drug. 
MTX PHARMACOKINETICS
The landmark studies demonstrating efficacy of  MTX in 
Crohn’s disease (CD) have utilized sq or im at 25 mg/wk. 
Smaller non-randomized studies in both CD and UC 
patients have offered conflicting data and, to an extent 
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demonstrate, the relative ineffectiveness with low dose 
po regimens for induction or maintenance of  remission 
(Table 1)[4,5]. Jundt demonstrated similar bioavailability 
between po vs sq vs im MTX in RA patients[6]. The bio-
availability of  po as compared to im was 0.85. 
Kurnik et al[7] studied the bioavailability of  MTX in 
adult patients with stable Crohn’s disease. The patients 
were administered their weekly doses either orally or sq 
and the MTX levels were measured over the next 24 h. 
No information on extent of  small bowel inflammation 
was provided. They found that oral bioavailability aver-
ages 73% (95%CI: 62%-86%) of  that of  subcutaneous 
administration[7]. Hoekstra demonstrated that the bio-
availability of  po MTX can be boosted by split dosing. RA 
patients were studied after single dosing of  MTX by ei-
ther sq or po method. Then the same patient underwent a 
second measurement after split dosing of  MTX (50% of  
the dose taken 8 h later). The bioavailability of  the split 
dose was 28% higher compared to the single dose (P = 
0.007) and was statistically significant. The mean bioavail-
ability after single-dose and split-dose MTX was 0.76 and 
0.90, respectively, compared to subcutaneous administra-
tion[8]. 
Wilson et al[9] updated the Kurnik study using a more 
sensitive assay. They compared the pharmacokinetic 
profile of  po and subcutaneous MTX (25 mg) in 11 CD 
patients. The bioavailability of  po MTX compared with 
sq was found to be 0.86 (90%CI: 0.79-0.92). Of  note, the 
90%CI to meet definition of  bioequivalency proposed by 
the FDA was not met, (lower end of  the 90%CI would 
have had to be 0.80 rather than 0.79), and so this study 
could not claim true bioequivalency of  the oral and sq 
routes of  administration. 
Although these are small studies and many patient 
factors were not provided (i.e., extent and severity of  
bowel disease), the po route of  administration does ap-
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Table 1  Summary of methotrexate trials in Crohn’s disease
Study Dose MTX Route of 
admin
n Study design Patients Duration 
follow 
up (wk)
MTX 
response 
MTX 
remission 
Placebo or 
(Comparator)  
Response
AE 
MTX
AE 
Placebo 
Kozarek 25 mg/wk sq 14 Non-
Randomized-
open Label
CD 12 79%
Feagan 25 mg/wk im 141 Double-
blind Placebo 
controlled 
multi center
Steroid 
dependent 
CD
16 39.4%1 19.1% 1% 2%
Oren 12.5 mg/wk po 84 Randomized 
Double-
Blind Placebo 
Controlled
Active CD 36 38% 46%
Arora 22.5 mg/wk po 33 Randomized 
Double Blind 
Placebo 
Controlled
Steroid 
Dependent 
CD
52 54% 20% 23% 0
Feagan 15 mg/wk im 76 Double Blind 
Placebo 
Controlled 
Multi-Center
CD 
Maintenance
40 65%1 39% 1% 2%
Mate-
Jimenez
15 mg/wk po 38 Randomized 
Single Center
Steroid 
Dependent 
CD
76 80%1 Induction
66.6%1 
Maintenance
14% Induction
0  
Maintenance
11.5% 0
Lemann 25 mg/wk im 49 Retrospective Active CD 84% 49%
Fraser 20 mg/wk 
(10-25)
po/im 48 Retrospective Active CD-
Maintenance
62% 27%
Ardizzone 25  mg/wk iv 54 Investigator 
Blind, 
randomized
Active CD 24 56% 63% AZA 11%
Mahadevan 25 mg/wk im 16 Retrospective 
case series
Fistulizing 
CD
56% 6%
Wahed 25 mg/wk 
Induction
15 mg/wk
Maintenance
im/po-
Induction
po-
Maintenance
99 Retrospective AZA 
Intolerance/
AZA non-
responders
62% 8.3%
Feagan Wk0-10 mg/wk
Wk3-20 mg/wk
Wk5-25 mg/wk
sq 126 Double Blind 
Placebo 
Controlled 
Multi-center
Active CD 50 IFX + MTX
56%
IFX + PCBO
57%
1P < 0.05 vs MTX response. MTX: Methotrexate; CD: Crohn’s disease; AE: Adverse events; AZA: Azathioprine.
pear to be less bioavailable than sq dosing. 
WHAT IS THE DATA FOR MTX IN 
INDUCTION OF REMISSION IN STEROID 
DEPENDENT CROHN’S DISEASE?
Although Kozarek et al[10] (NEJM 1980) had demonstrat-
ed the efficacy of  6-mercaptopurine in the induction of  
remission of  Crohn’s disease, the authors noted the re-
sponse to be delayed and incomplete. The first report of  
successful induction with methotrexate was reported by 
Kozarek et al[10] in 1989. This non-randomized, open-label 
pilot study included 14 patients with Crohn’s disease with 
an unidentified fraction described as failing immuno-
modulators. Eleven patients (79%) demonstrated a clini-
cal response to 25 mg/wk im methotrexate as measured 
by objective decreases in CDAI, and 5 patients (36%) 
demonstrated endoscopic mucosal healing. Although this 
study lacked a control arm, it suggested MTX may have 
value in inducing remission in patients with Crohns’ dis-
ease.
Feagan completed a prospective double-blind, place-
bo-controlled Canadian multicenter study of  weekly im 
injections of  methotrexate in patients who had chronical-
ly active Crohn’s disease despite a minimum of  3 mo of  
prednisone therapy with the primary outcome being the 
induction of  clinical remission[11]. A total of  141 patients 
assigned in a 2:1 ratio of  MTX to placebo were included 
in the trial and 37 (39.4%) achieved clinical remission in 
the methotrexate group compared with 9 (19.1%) in the 
placebo group (P = 0.025). The response among patients 
requiring high dose prednisone (> 20 mg/d) was equally 
good as those requiring low doses at study initiation. 
Prednisone dose was appreciably lower by week 4 in the 
MTX group and demonstrated the largest difference 
from week 12 through 16. A greater number of  patients 
withdrew from the treatment arm due to adverse events 
(17% vs 2%). The withdrawals from the MTX arm were 
due to asymptomatic elevation of  serum aminotransfer-
ase concentrations (7), nausea (6), skin rash (1), atypical 
pneumonia (1), and optic neuritis (1). 
Oren et al[5] conducted a prospective randomized, 
double blind, placebo-controlled Israeli multi-center trial 
to evaluate the effectiveness of  oral methotrexate in pa-
tients who had required steroids or immunomodulators 
for at least 4 mo out of  the year prior to enrollment. Al-
though it would be difficult to characterize these patients 
as steroid dependant, they had active ongoing disease as 
measured by Harvey Bradshaw Index. The study ran-
domized 84 patients to 12.5 mg po MTX/week vs 6-MP 
50 mg/daily vs placebo. The lower dose of  oral MTX 
(compared to 25 mg/wk im in the Feagan study) was 
based on reported efficacy in the rheumatoid arthritis lit-
erature. Remission rates were 39% and 41% in the MTX 
and 6-MP groups respectively. However, the rate of  re-
mission in the placebo group was 46%, thereby inferring 
no benefit for either the MTX or 6 MP treatment arm. 
Criticisms of  this study included presumed underdosing 
of  MTX and 6 MP. Also, no standard steroid tapering 
regimen was described in this study, although reduction 
in steroid dose was described as an outcome measure. 
Although improvement was seen based on intra-patient 
evaluation (each patient used as their own control), this 
was not a pre-specified analysis. Hence, these results 
should be viewed with caution. 
A cohort of  38 patients with steroid dependant CD 
was evaluated by Mate-Jimenez, but the requirement to 
separate these patients into 3 arms (1.5 mg/kg per day 
6MP, 15 mg/wk po MTX, or 5-ASA) resulted in a small 
number of  patients in each arm[12]. However, the large 
differences in outcomes for induction of  remission in 
both treatment arms (93.7% 6MP, 80%MTX) compared 
to placebo (14%) was statistically significant. Interestingly, 
these findings show a degree of  benefit that has not been 
reproduced for either the 6MP or MTX treatment arms. 
Arora et al[13] evaluated 28 steroid-dependant Crohn’s dis-
ease patients who received 15 mg/wk po MTX vs placebo. 
Dose escalation to 22.5 mg/wk was allowed at the discre-
tion of  the clinician. The primary endpoint was clinical 
exacerbation of  Crohn’s disease. Although fewer patients 
in the MTX group (6/13, 46%) experienced exacerba-
tion of  CD vs placebo (12/15, 80%), the findings did not 
reach statistical significance. Despite the 43% relative risk 
reduction in flare frequency between the treatment and 
placebo, this study was underpowered to find this differ-
ence to be significant. 
Ardizzone evaluated the efficacy of  iv MTX in com-
parison to AZA[4]. This randomized investigator-blind 
study enrolled 54 steroid-dependent active (CDAI > 200) 
CD patients on > 10 mg/d of  steroid therapy. Patients 
were randomized to 25 mg iv/wk of  MTX vs po AZA 2 
mg/kg per day for 3 mo, after which MTX dosing was 
changed to 25 mg/wk po for an additional 3 mo follow 
up. The primary outcome considered was the proportion 
of  patients entering steroid-free remission after 3 and 6 
mo of  therapy. No statistically significant difference was 
found between the two treatment regimens with respect 
to remission rate after 3 mo (methotrexate 44%, azathio-
prine 33%, P = 0.28, (95%CI: 0.369-0.147), and 6 mo 
(methotrexate 56%, azathioprine 63%, P = 0.39, 95%CI: 
0.187-0.335), respectively. MTX and AZA demonstrated 
similar rates of  adverse events leading to medication 
withdrawal. While there appeared to no additional benefit 
to providing MTX via the IV route, MTX at 25 mg/wk 
appeared to have similar efficacy as weight based aza-
thioprine in inducing and maintaining remission in active 
Crohn’s disease.
A 2011 meta-analysis of  MTX in active Crohn’s did 
not include either the Mate-Jiminez or Ardizzone studies 
(no placebo arm) or Arora studies (categorized the study 
patients as quiescent)[14]. Their conclusion that MTX was 
not better than placebo in active Crohn’s was based only 
on the inclusion of  Feagan’s positive trial (25 mg/wk 
im MTX) and the negative orally administered MTX 
(12.5 mg/wk po) Oren trial. The Cochrane collaboration 
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AZA and had already been treated with MTX for period of  
at least 6 mo were followed for an additional 18 mo[21]. 
Out of  49 patients, 42 had previously failed AZA (85%). 
Out of  the 41 achieving remission, 36 had previously 
failed AZA (87%). Most of  the patients were adminis-
tered 25 mg/wk im MTX, but some physicians changed 
the dose to oral administration and some were even able 
to taper it. Despite some patients with oral MTX dosing 
and despite a heavy proportion of  AZA failures in the 
study population, 71% of  the study population remained 
in remission for 1 year and up to 52% remained in remis-
sion after 3 years. Among patients who initially do well 
on MTX after AZA failure, they are likely to remain well 
on that therapy over the next several years.
Wahed et al[22] evaluated clinical response of  99 CD 
patients retrospectively who were placed on MTX due to 
AZA intolerance or nonresponse. The study suffers from 
a non-homogenous doses and method of  administration 
of  MTX for induction and maintenance. The range of  
induction dose of  MTX was 2.5-25 mg/wk and adminis-
tration varied as either im or po. Improvement was based 
on multiple variables as available from the charts, but was 
not standardized. With these caveats, clinical response 
occurred in 18 of  29 patients (62%) refractory to AZA/
MP and 42 of  70 patients (60%) intolerant to AZA/MP. 
This suggests that MTX is effective in CD patients previ-
ously treated with AZA who experienced failure or non-
response. 
At present, there are no high quality trials (prospec-
tive, identical induction doses and method of  adminis-
tration, presence of  control groups) on which to confi-
dently choose to use MTX specifically in a population of  
AZA/6MP failures, but it would not be unreasonable to 
attempt MTX. 
DOES COMBINATION MTX AND ANTI-
TNF THERAPY TO TREAT CROHN’S 
DISEASE RESULT IN BETTER 
OUTCOMES?
The landmark SONIC study demonstrated that patients 
with moderate-to-severe Crohn’s disease who were treat-
ed with combination infliximab plus azathioprine were 
more likely to have a corticosteroid-free clinical remission 
than those receiving azathioprine or infliximab mono-
therapy[23]. Concomitant immunosuppressive therapy also 
reduces the magnitude of  the immunogenic response 
of  infliximab[24]. It follows that methotrexate, as part of  
combination therapy with anti-TNF agents, may provide 
similar benefits. 
Feagan et al[25] studied this hypothesis in the COM-
MIT trial. They performed a 50-wk double-blind, place-
bo-controlled trial of  MTX + IFX vs IFX monotherapy 
in Crohn’s patients who had started prednisone therapy 
within the preceding 6 wk. Patients were not permitted 
to use any other therapy with the exception of  antibiot-
ics for 14 d in the case of  active perianal disease. Patients 
reached similar conclusions a year later, but understood 
the limitations of  the data on oral MTX and suggested 
further study[15]. 
WHAT IS THE DATA FOR MTX IN 
MAINTENANCE OF STEROID-FREE 
REMISSION IN CROHN’S DISEASE?
Feagan demonstrated the use of  MTX in Crohn’s disease 
for maintenance of  remission in a large double-blind, 
placebo controlled multi-center study with 76 patients in 
2000[16]. Some of  these patients were enrolled from Fea-
gan’s trial for induction of  remission using 25 mg im/wk 
MTX in 1995 and others from an open label trial of  25 
mg/wk im MTX. The patients were randomized to 15 
mg im MTX/weekly vs placebo and followed for 40 wk. 
Impressively, no other therapy for Crohn’s disease was 
permitted. At the completion of  the trial 65% (26/40) of  
the MTX group maintained remission compared to 39% 
(14/36) of  the placebo group (P = 0.04). A majority (55%) 
of  the relapsers could be re-induced with 25 mg/wk im 
MTX. Adverse events were minimal as only 1 patient dis-
continued MTX therapy for nausea and vomiting. 
The efficacy of  oral MTX (10-20 mg po) for maintenance 
of  remission in Crohn’s and ulcerative colitis was evaluated 
by a retrospective review by Fraser. Although 1 year remis-
sion rates approached 90%, the data for Crohn’s and UC 
were combined and the clinical definition of  remission 
was vague[17]. 
Given the dearth of  high quality studies of  MTX in 
maintaining remission in Crohn’s, the only maintenance 
study used in the Kahn meta-analysis was Feagan’s (15 
mg im/wk MTX) suggesting benefit with a number need-
ed to treat (NNT) of  4[14]. Interestingly, the Cochrane 
meta-analysis of  MTX for maintenance of  remission, 
included both the Mata-Jimenez study and Oren studies 
as part their analysis[18]. Their main conclusions track the 
benefit shown by the Feagan’s 15 mg/wk im MTX and 
suggest that lower oral doses do not benefit maintenance 
of  remission. 
CAN MTX BE USED IN PATIENTS WHO 
FAIL AZA AND HOW DURABLE IS THE 
RESPONSE TO MTX?
Despite the widespread use of  thiopurines, approxi-
mately one third do not respond and another 10% can-
not tolerate the drugs[19]. In the United States, MTX is 
often reserved for AZA intolerance or failure and fewer 
physicians are comfortable prescribing it[20]. AZA Intoler-
ance can include bone marrow suppression, upper GI 
symptoms, pancreatic dysfunction, abnormal LFT’s and 
nonspecific symptoms including joint aches, hair loss, 
rash and flu like illness.
A study by Lemann in 2000 evaluated the durability 
of  MTX for maintenance of  remission in a population 
of  patients who had (mostly) failed or were intolerant to 
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were initiated on IFX 5 mg/wk and 10 mg sq MTX/week 
(escalating to 25 mg/wk by week 5) or IFX 5 mg/wk 
and placebo injections. Prednisone was force tapered in 
all patients by week 14. The primary outcome evaluated 
steroid free-remission by week 14 or maintenance of  
remission by week 50. Steroid-free remission at week 14 
was 76% (48/63) in combination therapy compared to 
78%(49/63) with IFX mono therapy (P = 0.83). At week 
50, 56%(35/63) vs 57%(36/63) maintained remission in 
the combination arm vs monotherapy arm. Mean metho-
trexate doses at week 50 in the treatment arm was 22.3 
mg/wk. This study found that combination therapy with 
IFX and MTX had no more benefit than IFX alone. 
Based on the strongest current body of  evidence 
(SONIC, COMMIT), it seems reasonable to prefer com-
bination therapy using AZA/6MP rather than MTX in 
those Crohn’s patients able to tolerate it. 
IS MTX EFFECTIVE IN PREVENTING 
AUTO-ANTIBODY FORMATION WHEN 
USED IN COMBINATION WITH BIOLOGIC 
THERAPY?
A prospective study by Vermeire evaluated the develop-
ment of  antibodies to infliximab (ATI) when combined 
with AZA, MTX, or placebo[26]. The concomitant use of  
immunosuppressive therapy (MTX or AZA) was associ-
ated with a lower incidence of  antibodies to IFX (53/115, 
46%) compared with patients not receiving concomitant 
immunosuppressive therapy (43/59, 73%; P < 0.0001). 
Furthermore, the incidence of  antibody formation was 
not different between the MTX and AZA groups, 44% 
compared to 48% respectively. Patients not taking IS 
therapy had lower IFX levels (median 2.42 mcg/mL) 4 
wk after any follow-up infusion than patients taking con-
comitant IS therapy (median 6.45 mcg/mL) (P = 0.065), 
but there was no difference between MTX or AZA. So-
kol et al[27] confirm that patients using co-treatment with 
immunosuppressives experienced less IBD activity and 
less need to switch Anti-TNF therapy due to secondary 
loss of  response. In fact, their data suggest efficacy of  
AZA over MTX, though their patient population includ-
ed both CD and UC patients, and it is not clear whether 
any of  the UC patients were treated with MTX and in-
cluded in the analysis.
Although the COMMIT study did not show an im-
provement in 50 wk outcomes using combination ther-
apy (IFX + MTX vs IFX alone), the MTX combination 
group did achieve statistically significant lower antibody 
levels (4% compared with 20%, P = 0.01) and demon-
strated higher median serum trough levels of  IFX (6.35 
µg/mL vs 3.75 µg/mL, P = 0.08), similar to what is seen 
with azathioprine combination therapy[25]. Whether this 
would result in fewer instances of  infusion reactions or 
secondary non-response to IFX beyond 50 wk remains 
to be seen.
CAN MTX BE USED TO MANAGE 
SECONDARY NONRESPONSE TO 
BIOLOGIC MONOTHERAPY?
Absah retrospectively evaluated 14 pediatric patients with 
moderate to severe (CD) eventually failing anti-TNF-α 
therapy (13 ADA and 1 IFX) who then received concom-
itant methotrexate (median dose 17.5 mg sq/wk)[28]. Most 
(12/14) patients had also previously failed AZA therapy 
(though it is not made clear whether this was as part 
of  combination with biologic). Clinical remission was 
achieved in 7/14 (50%) of  patients on average of  6 wk 
after MTX initiation with no additional improvement in 
the other 7 patients during 10 mo of  follow up. Unfortu-
nately, no levels of  biologic or antibody to biologic were 
measured in this study, so the mechanism of  improve-
ment remains unknown. Further research focusing on the 
adult population along with mechanism of  action would 
serve to direct therapy in this refractory population often 
seen in tertiary centers. 
DOES MTX TREAT FISTULIZING CROHN’S 
DISEASE?
To date, only small retrospective series are available to 
evaluate the efficacy of  MTX monotherapy in fistuliz-
ing Crohn’s disease. A research conducted a retrospective 
chart review of  all Crohn’s disease receiving methotrexate 
15-25 mg im MTX/weekly. This group of  patients that 
had failed or were intolerant to 6MP and were made up 
of  perianal fistulae (9), abdominal wall (3), rectovaginal 
(1), bladder (1), perianal + rectovaginal (2). Overall, 4/16 
(25%) experienced complete fistula closure and 5/16 
(31%) had partial fistula closure. Fourteen of  sixteen pa-
tients received full dose 25 mg im/wk of  MTX for 3 mo 
and were switched to po for maintenance. The time to 
response could not be determined in half  of  the patients, 
but ranged from 4-13 wk in the other half. Another study 
found that 8/18 (44%) patients with Crohn’s-related fis-
tulas achieved partial or complete response using MTX 
for 6 mo, but information about success and failure based 
on oral or im administration was not provided[29]. A pilot 
study of  12 patients using combination infliximab and 
MTX found 7 patients had total or partial response to 
fistula, but there was no MTX only arm and the data seem 
similar to the benefit achieved with IFX monotherapy[30,31]. 
Approximately 10% of  peri-anal and abdominal fistulas 
in Crohn’s heal spontaneously[31]. Given a closure rate well 
above the spontaneous closure rate, we consider MTX a po-
tentially useful adjunct in management of  Crohn’s fistulas.
METHOTREXATE AND ULCERATIVE 
COLITIS 
Does MTX work for induction of remission in UC?
Evidence pertaining to the utility of  methotrexate in 
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induction of  remission for ulcerative colitis is conflict-
ing (Table 2). Disparate results reflect disagreement over 
appropriate dosing and route of  administration. To date, 
only one prospective, randomized placebo-controlled trial 
examining the efficacy of  methotrexate in the treatment 
of  ulcerative colitis exists; Oren et al[5]  in 1996 compared 
12.5 mg oral methotrexate to placebo in the induction of  
remission of  67 patients with moderate/severe UC[5,14]. 
All patients had active disease with a Mayo score of  >7, 
and were taking steroids for at least 4 mo in the preced-
ing year. The results were disappointing, with clinical re-
mission rates of  46.7% (14/30) in the methotrexate arm 
in comparison to 48.6% (18/37) for the placebo arm, a 
non-significant difference. Of  those who entered clini-
cal remission, 64.3% of  patients in the methotrexate arm 
had a relapse requiring steroid induction compared to 
44.4% of  placebo patients, again, an insignificant differ-
ence. 
Overall, a low remission rate relative to placebo, long 
time to remission, and a high relapse rate in Oren’s study 
all suggest a lack of  efficacy for methotrexate in either 
the induction or maintenance of  remission in ulcerative 
colitis. Of  course, important criticism may be directed at 
the relatively low dose of  MTX used and the oral route 
of  administration. 
Otherwise, a number of  small open-label and larger 
retrospective analyses have been conflicting, not least due 
to differing definitions of  response, length of  follow up 
(12 wk-2 years), dose of  MTX (7.5-25 mg/wk), and route 
administered (po vs im). None of  these studies were con-
sidered of  sufficient quality to be included in the meta-
analysis by Khan et al[14]. 
The most comprehensive of  these was published last 
year by Khan et al[32], presenting retrospective data regard-
ing experience with methotrexate in the Veterans Affairs 
(VA) system. A total of  91 patients with ulcerative colitis 
who were steroid dependent or refractory were com-
menced on oral (mean 14 mg) or parenteral (mean 25 
mg) methotrexate. In the oral MTX cohort, 37% (25/68) 
were able to successfully wean from steroid therapy, com-
pared to 30% (7/23) of  the parenteral cohort. 
Overall, looking specifically at induction of  remis-
sion in ulcerative colitis, response to methotrexate ranged 
from 27%-100%, and remission rates ranged from 
0%-63%. Considering the retrospective nature of  most 
studies, it is impossible to determine the true impact of  
dose or route of  administration. In prospective, open 
label or randomized controlled trials, response rates simi-
larly ranged from 33%-100%, with remission rates rang-
ing 17%-60%. There are no clear signals regarding the 
impact of  dose, route of  administration, or indication for 
step-up in therapy on remission or response rates in UC. 
Does MTX work for maintenance of remission in UC?
Regarding the maintenance of  remission, the results are 
equally confusing - maintenance of  remission rates range 
from 14%-75% (Table 3). Unfortunately, two open-
labeled studies suggesting successful maintenance rates 
> 60%[10,33] using parenteral methotrexate did not include 
a placebo arm as comparison[10,33]. Oren et al[5] and Mate-
Jimenez et al[12] included control arms, but provided dis-
appointing results for the efficacy of  oral methotrexate. 
Whether the route is a factor for better response rates 
remains to be seen. 
There has been no data to date investigating the utility 
of  combining methotrexate with biologic therapy in UC. 
Increasing interest in using methotrexate as a “synergistic 
enhancer” - to augment and prolong biologic efficacy - 
Table 2  Evidence for induction of remission of ulcerative colitis with methotrexate
Study Dose (mean) Route No. of patients Study design Follow-up (wk) MTX response MTX remission Placebo response
Kozarek 25 mg im 7 Open label 12 5/7 (71.40%) N/A
Baron 15 mg Oral 8 Open label 18 3/8 (37.5%) 0 N/A
Oren 12.5 mg Oral 67 Placebo 
control
36 14/30 (46.7%) 18/37 (48.6%)
Egan 15 mg
25 mg
sc
sc
18
12
Open label 16 7/18 (39%)
 4/12 (33%)
3/18 (17%)
2/12 (17%)
N/A
N/A
Mate-Jimenez 15 mg Oral 34 6-MP control 30 7/12 (58.30%) 11/14 (78.6%)
Paoluzi 12.5 mg im 10 thiopurine resistant/
intolerant
Open label 26 10/10 (100%) 6/10 (60%) N/A
Cummings 1 9 . 9  m g 
mean
Oral 11 AZA failure
31 AZA intolerant
Retrospective 30 3/11 (27%)
18/31 (58%) 14/31
N/A
Nathan 20-25 mg sc/
oral
23 Retrospective N/A 11/23 (48%) N/A
Wahed 10-25 mg Oral, 
sc
9 thiopurine ineffective
23 thiopurine intolerant 
Retrospective 26 7/9 (78%)
15/23 (65%)
N/A N/A
Manosa 25 mg Oral
sc
7
33
Retrospective 26 24/40 
(60%) remission
N/A
Saibeni 20 mg Oral/
sc/im
23 Retrospective N/A 11/23 (47.8%) N/A
Khan 14 mg
25 mg
Oral
sc/im
68
23
Retrospective 60 25/68 (37%)
7/23 (30%)
N/A
MTX: Methotrexate; CD: Crohn’s disease; AE: Adverse events; SC: Subcutaneous; PO: Oral; AZA: Azathioprine.
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may help define its role in this disease. 
PRACTICAL ADVICE ON HOW TO 
PRESCRIBE MTX IN THE US
Injectable MTX is available in 50 mg/2 mL vials. We 
prescribe one vial (2 loading dose equivalents) as well as 
a supply of  “tuberculin” 1 mL syringes with 27 guage, 
1/2” needles. The patient draws 25 mg weekly from the 
vial and injects subcutaneously in either lower quadrant 
of  the abdomen or inner thighs as their preference. After 
12 wk, if  they have a response, they can be transitioned 
to oral methotrexate maintenance. A patient friendly 
resource on injecting MTX is available via the Canadian 
rheumatology association (http://rheuminfo.com/wp-
content/uploads/2011/04/METHOTREXATE_INJEC
TION_SHEET.pdf).
Oral methotrexate is available in 10 and 15 mg strengths 
as Trexall™. If  using oral methotrexate in the induction 
of  remission of  IBD, we would recommend starting with 
25 mg weekly, reverting to the subcutaneous route in non-
responders and those who develop nausea attributed to the 
oral route. 
All patients should be prescribed folic acid 1mg daily 
as it significantly reduces hepatic toxicity, an infrequent 
occurrence, and gastrointestinal toxicity associated with 
MTX[34,35]. At present, our target population for MTX 
are CD patients who are unable to tolerate azathioprine 
or 6Mercaptopurine due to adverse events, homozygous 
TMPT mutations, or inefficacy.  In the event that metho-
trexate is required in a woman of  child bearing age, we 
counsel regarding the need for effective contraception 
(i.e., IUD) and recommend a discussion with their obstet-
ric physician. We advocate obtaining routine blood labs 
(complete blood count, basic chemistry panel, hepatic 
function panel) 1 wk after initiation as well as every 8-12 
wk subsequently.
CONCLUSION
Given the current evidence an algorithm for MTX can 
be elucidated (Figure 1). Providers should no longer shy 
away from using MTX due to concerns of  hepatotoxic-
ity and intolerance. Methotrexate demonstrates a similar 
rate of  drug withdrawal as AZA, and may be considered 
favorable in young males in whom practitioners are re-
luctant to use AZA (due to concerns of  hepato-splenic 
T-cell lymphoma risk). Determining the optimal dose and 
route of  administration in the various indications for use 
in IBD is the current priority. MTX is largely used as a 
second line therapy after AZA failure. It may be useful 
in combination with Anti-TNF therapy to reduce the risk 
of  immunogenicity and subsequent secondary loss of  re-
sponse to anti-TNF therapy. We eagerly await the results 
Table 3  Evidence for maintenance of remission of ulcerative colitis with methotrexate
Study Dose (mean) Route No. of pts Study design Follow-up 
period (mo)
MTX response 
maintained?
Control 
response
Significantly 
effective?
Kozarek > 7.5 mg sc   5 Open label 24 3/5 (60%) N/A N/A
Oren 12.5 mg oral 32 Placebo-
controlled
  9 5/14 (36%) 10/18 (56%) No
Mate-Jimenez 15 mg oral 12 6-MP control 18 1/7 (14%) 7/11 (64%) No 
Paoluzi 12.5 mg im 10 Open label 24 6/8 (75%) N/A N/A
Manosa 25 mg Oral/   7 Retrospective 24 35% N/A
sc 33
MTX: Methotrexate.
Crohn’s
Induction of remission
Maintenance of remission
Induction of remission
Maintenance of remission
Ulcerative colitis
Effective parenterally at 25 mg 
Not effective at low doses (12.5 mg) orally
Fistulizing disease: Effective, through  route/dose unclear.
Combination therapy: Suppresses antibody to IFX, but doesn’t 
improve steroid free remission at 1 yr.
Anti-TNF failures: Effective parenterally as 
Effective parenterally at 15 mg
May be effective orally, dose unclear
In AZA failures: may be effective
Not effective at low doses (15 mg) orally
May be effective parenterally at 25 mg dose
Unknown benefit with biologics
Not effective orally
May be effective parenterally regardless of dose
May be effective when used in combination with biologics
Methotrexate
Figure 1  Algorithm for evidence-based use of methotrexate in inflammatory bowel disease. AZA: Azathioprine.
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of  two studies that will shed further light; the METEOR 
trial and MERIT-UC, both randomized, controlled trials 
of  parenteral MTX 25 mg weekly in the induction and 
maintenance of  remission in steroid dependent or refrac-
tory ulcerative colitis.
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